Ligand Pharmaceuticals (NASDAQ:LGND) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.
Several other analysts have also commented on LGND. HC Wainwright restated a “buy” rating and issued a $157.00 price objective on shares of Ligand Pharmaceuticals in a report on Monday, November 6th. Roth Capital set a $158.00 price objective on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 13th. Craig Hallum restated a “buy” rating and issued a $170.00 price objective (up from $160.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, November 15th. Deutsche Bank lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and set a $105.00 price objective for the company. in a report on Monday, November 20th. Finally, Zacks Investment Research lowered shares of Ligand Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 30th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $157.33.
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) opened at $151.89 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.97 and a current ratio of 0.99. The firm has a market cap of $3,210.00, a PE ratio of 73.73, a PEG ratio of 1.63 and a beta of 1.07. Ligand Pharmaceuticals has a 1-year low of $101.43 and a 1-year high of $170.30.
In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $145.00, for a total transaction of $362,500.00. Following the completion of the transaction, the director now owns 33,149 shares of the company’s stock, valued at $4,806,605. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen L. Sabba sold 925 shares of the firm’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $137.25, for a total transaction of $126,956.25. Following the transaction, the director now directly owns 26,985 shares of the company’s stock, valued at approximately $3,703,691.25. The disclosure for this sale can be found here. Insiders sold 89,055 shares of company stock valued at $13,912,694 over the last 90 days. 8.30% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in LGND. Assetmark Inc. increased its stake in shares of Ligand Pharmaceuticals by 336.4% during the fourth quarter. Assetmark Inc. now owns 1,056 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 814 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Ligand Pharmaceuticals by 48.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,101 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 359 shares in the last quarter. We Are One Seven LLC bought a new position in shares of Ligand Pharmaceuticals during the fourth quarter valued at approximately $179,000. Ameritas Investment Partners Inc. increased its stake in shares of Ligand Pharmaceuticals by 9.4% during the second quarter. Ameritas Investment Partners Inc. now owns 1,799 shares of the biotechnology company’s stock valued at $218,000 after purchasing an additional 154 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of Ligand Pharmaceuticals during the third quarter valued at approximately $230,000.
WARNING: “Ligand Pharmaceuticals (LGND) Lowered to Buy at BidaskClub” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3229394/ligand-pharmaceuticals-lgnd-lowered-to-buy-at-bidaskclub.html.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.